NTN1 and hepatocellular carcinoma: Sorafenib, the approved targeted therapy against HCC,70 fosters HCC cell death through antiangiogenic activity71 and inhibition of the UPR.72, 73, 74 It is possible that, as is the case for any dynamic process in biology, dual targeting of the UPR using sorafenib and netrin-1 in HCC may decrease the dependency of HCC cells toward netrin-1 for cell survival.